All News
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).
Read Article
Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duration of lumbar AM stiffness were not affected by FM, yet FM significantly caused higher scores in axSpA or PsA all assessments https://t.co/v8wFzIVxUr https://t.co/eIXRoktYja
Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/TIdCtJjF21 https://t.co/UE0nGbESDB
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 136 referred LBP pts (71 w/ DDD, 38 DISH, 27 axSpA) found significant overlap of imaging features in all 3. SpA-like spine CR features were found in 1/4 of patients with DISH, and MRI BM edema found in 1/3 of those patients. https://t.co/dKIcuE3IGZ https://t.co/OITtOKEuNC
Dr. John Cush RheumNow ( View Tweet)
New Classification Criteria for Juvenile Axial Spondyloarthritis
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
https://t.co/kxtHlEk5XG https://t.co/jKAp9W5Di1
Dr. John Cush RheumNow ( View Tweet)
New Classification Criteria for Juvenile Axial Spondyloarthritis
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
https://t.co/ZR5pFINagR https://t.co/bEWjSXWlB0
Dr. John Cush RheumNow ( View Tweet)
UK study of pneumococcal vaccination in UK, shows IMID pts had suboptimal vax against pneumococcus. In 32 277 pts (RA 14151, IBD 13631, SpA 3804, SLE 691) saw 57% vaccinated; lower if <45 yrs (32%), IBD (42%). Vax not associated w/ IMID flare https://t.co/y5JHYaEpA9 https://t.co/zUXfDoqyal
Dr. John Cush RheumNow ( View Tweet)
Pollution and Autoimmunity (7.12.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Bimekizumab (dual-IL-17A/F inhib), may prevent uveitis in patients with axSpA. In phase 3 RCTs (MOBILE 1 & 2) double-blind period, uveitis seen in 0.6% on BKZ vs 4.6% on PBO (p=0.001). In pts w/ hx uveitis, again lower w/ BKZ (6.2/100 PYs vs 70.4/100 PYs) https://t.co/v0wMK45chz https://t.co/CVPdg1k41V
Dr. John Cush RheumNow ( View Tweet)
Paradoxical psoriasis w/ IL-17 inhib? Lit review 35 (SpA) pts, presenting as palmoplantar pustular and plaque PsO; median 11 weeks after IL-17i. one-third continued IL-17i w/ mostly topical Rx; 2/3 D/C IL-17i, switching to other biologic w/ good outcomes https://t.co/q2xqQyiM3b https://t.co/6hSE6NLHWw
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Dead Words Eulogy
The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical subspecialties.
Read Article
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.
#EULAR2024
Dr. John Cush RheumNow ( View Tweet)
Imaging in Axial Spondyloarthritis
Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.
https://t.co/SqTi4Xvoo2 https://t.co/TzZdUEkOXW
Dr. John Cush RheumNow ( View Tweet)
Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.
https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J
Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G
Dr. John Cush RheumNow ( View Tweet)
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article
Lit. cohort analysis of >330K #AS shows higher risk of cancer (RR=1.16: 1.07–1.26); w/ higher risk in Asia, but not Europe. Increased CA risk for : bone (RR 3.41), thyroid(1.76), myeloma (1.74), leukemia (1.52), kidney (1.45), prostate (1.43), NHL (1.42) https://t.co/disRefur0l https://t.co/ffjED0Ftvc
Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13
Dr. John Cush RheumNow ( View Tweet)
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024
Dr. John Cush RheumNow ( View Tweet)